SECOND LINE ERLOTINIB IN NON-SMALL CELL LUNG CANCER: A LOCAL EXPERIENCE

被引：0
|
作者：
Smith, C. F. [1 ]
Garcia-Alonso, Angel [1 ]
Drury, G. [1 ]
Gostage, A. [1 ]
Smith, N. [1 ]
机构：
[1] Betsi Cadwaladr Univ Hlth Board, N Wales Canc Treatment Ctr, Bangor, Gwynedd, Wales
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
erlotinib; second line; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：S1180 / S1181
页数：2
相关论文
共 50 条
  • [31] Second-line treatment of advanced non-small cell lung cancer
    Gridelli, Cesare
    Ardizzoni, Andrea
    Ciardiello, Fortunato
    Hanna, Nasser
    Heymach, John V.
    Perrone, Francesco
    Rosell, Rafael
    Shepherd, Frances A.
    Thatcher, Nick
    Vansteenkiste, Johan
    De Petris, Luigi
    Di Maio, Massimo
    De Marinis, Filippo
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 430 - 440
  • [32] Considerations for second-line therapy of non-small cell lung cancer
    Stinchcombe, Thomas E.
    Socinski, Mark A.
    ONCOLOGIST, 2008, 13 : 28 - 36
  • [33] Second line treatment of non-small cell lung cancer with paclitaxel and gemcitabine
    Kakolyris, S
    Kourousis, C
    Androulakis, N
    Dimopoulos, MA
    Papadakis, E
    Tzannes, S
    Kotsakis, T
    Vardakis, N
    Merambeliotakis, N
    Kalbakis, C
    Xatzidaki, D
    Georgoulias, V
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1049 - 1049
  • [34] Initial experience with erlotinib in advanced non-small cell lung cancer in the Kingdom of Saudi Arabia
    Alolayan, A. A. M.
    Musaad, S.
    Bamefleh, H.
    Nounou, M.
    Jazieh, A. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] ERLOTINIB IN METASTATIC, EGFR WILD-TYPE, NON-SMALL CELL LUNG CANCER (NSCLC) AS SECOND OR FURTHER LINE OF THERAPY
    Hernandez, Alba
    Calera, Lourdes
    Alvarez, Maria
    Hernando, Jorge
    Torres, Irene
    Pajares, Isabel
    Madani, Julia
    Cebollero, Ana
    Anton-Torres, Antonio
    Artal, Angel
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1017 - S1017
  • [36] Erlotinib in non-small cell lung cancer (NSCLC) in Germany - A cost-saving second-line treatment option?
    Gabriel, A.
    Pirk, O.
    Kotowa, W.
    VALUE IN HEALTH, 2006, 9 (06) : A278 - A278
  • [37] Combination of quinacrine and erlotinib overcomes resistance to erlotinib in non-small cell lung cancer
    Dermavvan, Josephine Kam Tai
    Gurova, Katerina
    Pink, John
    Dowlati, Afshin
    De, Sarmishtha
    Naria, Goutham
    Sharma, Neelesh
    Stark, George
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [38] Second-line treatment for non-small cell lung cancer: data from single institution experience
    Lu Shun
    Zhang Yifei
    Cheng Baijun
    Chen Zhiwei
    Li Ziming
    Yu Yongfeng
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S696 - S696
  • [39] Experience with osimertinib in second-line treatment of non-small cell lung cancer at Nottingham University Hospitals
    Sadiq, M.
    Khan, S.
    Lopez-Escola, C.
    Arora, A.
    Hennig, I.
    Abdallah, S.
    Soomro, I.
    LUNG CANCER, 2020, 139 : S62 - S62
  • [40] The use of second or third line nivolumab in advanced non-small cell lung cancer: a west of Scotland experience
    Ali, C.
    Yahya, K.
    LUNG CANCER, 2018, 115 : S31 - S31
12345